Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor PCC

被引:0
作者
Zahir, Hamim [1 ]
Vandell, Alexander [2 ]
Desai, Madhuri [1 ]
Maa, Jen-Fu [3 ]
Dishy, Victor [4 ]
Lomelli, Barbara [5 ]
Feussner, Annette [6 ]
Feng, Wenquin [7 ]
He, Ling [8 ]
Grosso, Michael A. [9 ]
Lanz, Hans J. [9 ]
Brown, Karen S. [1 ]
机构
[1] Daiichi Sankyo Pharma Dev, Translat Med & Clin Pharmacol, Edison, NJ USA
[2] Daiichi Sankyo Pharma Dev, Clin Pharmacogen, Edison, NJ USA
[3] Daiichi Sankyo Inc, Biostat, Parsippany, NJ USA
[4] Daiichi Sankyo Pharma Dev, Expt Med, Edison, NJ USA
[5] Quintiles Inc, Early Clin Dev, Overland, KS USA
[6] CSL Behring GmbH, Preclin Rsch & Dev, Marburg, Germany
[7] Daiichi Sankyo Pharma Dev, Clin Biomarker Anal, Edison, NJ USA
[8] Daiichi Sankyo Pharma Dev, Clin Bioanal, Edison, NJ USA
[9] Daiichi Sankyo Pharma Dev, Clin Dev, Edison, NJ USA
关键词
Anticoagulants; Factor xa; Dose-response relation; drug; Anticoagulation;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:2116 / 2116
页数:1
相关论文
共 35 条
[21]   Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal [J].
Makhoul, Therese ;
Kelly, Gregory ;
Kersten, Brian ;
Nadler, Megan ;
Zammit, Christopher G. ;
Jones, Courtney M. C. ;
Scott, Rachael ;
Acquisto, Nicole M. .
THROMBOSIS RESEARCH, 2020, 194 :158-164
[22]   Discussion of "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa" [J].
Van Dusen, Rachel .
AMERICAN JOURNAL OF SURGERY, 2018, 215 (05) :780-781
[23]   Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates: A Randomized Clinical Trial [J].
Sarode, Ravi ;
Goldstein, Joshua N. ;
Simonian, Gregory ;
Hinterberger, Doris ;
Matveev, Dmitrii ;
Gareis, Michelle ;
Milling Jr, Truman J. .
JAMA NETWORK OPEN, 2024, 7 (08) :e2424758
[24]   Activated Prothrombin Complex Concentrate Versus 4-Factor Prothrombin Complex Concentrate for Vitamin K-Antagonist Reversal [J].
Rowe, A. Shaun ;
Dietrich, Scott K. ;
Phillips, John W. ;
Foster, Kaci E. ;
Canter, Joshua R. .
CRITICAL CARE MEDICINE, 2018, 46 (06) :943-948
[25]   Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate [J].
Majeed, Ammar ;
Meijer, Karina ;
Larrazabal, Ramiro ;
Arnberg, Fabian ;
Luijckx, Gert J. ;
Roberts, Robin S. ;
Schulman, Sam .
THROMBOSIS AND HAEMOSTASIS, 2014, 111 (02) :233-239
[26]   Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: a comparison between 3-factor and 4-factor prothrombin complex concentrates [J].
Spiezia, Luca ;
Rossetto, Valeria ;
Campello, Elena ;
Bulato, Cristiana ;
Radu, Claudia M. ;
Simioni, Paolo .
BLOOD COAGULATION & FIBRINOLYSIS, 2020, 31 (02) :127-131
[27]   High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage [J].
Davis, Spencer D. ;
Chauv, Stephanie ;
Hickman, Abby W. ;
Collingridge, Dave S. ;
Kjerengtroen, Sara ;
Fontaine, Gabriel, V .
THROMBOSIS RESEARCH, 2021, 208 :112-116
[28]   Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis [J].
Margraf, David J. ;
Brown, Sarah J. ;
Blue, Heather L. ;
Bezdicek, Tamara L. ;
Wolfson, Julian ;
Chapman, Scott A. .
BMC EMERGENCY MEDICINE, 2022, 22 (01)
[29]   PROSPECTIVE EVALUATION OF A FIXED-DOSE 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE PROTOCOL FOR URGENT VITAMIN K ANTAGONIST REVERSAL [J].
Bitonti, Michael T. ;
Rumbarger, Rachel L. ;
Absher, Randall K. ;
Curran, Lisa M. .
JOURNAL OF EMERGENCY MEDICINE, 2020, 58 (02) :324-329
[30]   Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate [J].
Peksa, Gary D. ;
Mokszycki, Robert K. ;
Rech, Megan A. ;
Maynard, Brian ;
Panos, Nicholas G. ;
Sweis, Rolla T. ;
DeMott, Joshua M. .
THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) :207-215